DE10207843A1 - Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen - Google Patents

Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Info

Publication number: DE10207843A1
Authority: DE; Germany
Prior art keywords: group; ring; alkyl; alkanediyl; radicals
Prior art date: 2002-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

DE10207843A

Other languages

German (de)

English (en)

Inventor

Thorsten Blume

Wolf-Dietrich Doecke

Wolfgang Halfbrodt

Joachim Kuhnke

Ursula Moenning

Bernd Elger

Herbert Schneider

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Schering AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-15

Filing date

2002-02-15

Publication date

2003-09-04

2002-02-15 Application filed by Schering AG filed Critical Schering AG

2002-02-15 Priority to DE10207843A priority Critical patent/DE10207843A1/de

2003-01-17 Priority to PL03371327A priority patent/PL371327A1/xx

2003-01-17 Priority to CA002475770A priority patent/CA2475770A1/en

2003-01-17 Priority to AU2003245523A priority patent/AU2003245523A1/en

2003-01-17 Priority to BR0307706-3A priority patent/BR0307706A/pt

2003-01-17 Priority to KR10-2004-7012557A priority patent/KR20040084909A/ko

2003-01-17 Priority to CNA038039923A priority patent/CN1756546A/zh

2003-01-17 Priority to RU2004127677/15A priority patent/RU2004127677A/ru

2003-01-17 Priority to PCT/EP2003/000467 priority patent/WO2003068225A1/de

2003-01-17 Priority to MXPA04007943A priority patent/MXPA04007943A/es

2003-01-17 Priority to UA20040907401A priority patent/UA81111C2/uk

2003-01-17 Priority to JP2003567407A priority patent/JP2005522447A/ja

2003-01-17 Priority to YU71304A priority patent/RS71304A/sr

2003-01-17 Priority to EP03739380A priority patent/EP1474138A1/de

2003-02-03 Priority to PE2003000119A priority patent/PE20030906A1/es

2003-02-11 Priority to UY27662A priority patent/UY27662A1/es

2003-02-12 Priority to ARP030100436A priority patent/AR039556A1/es

2003-02-14 Priority to TW092103072A priority patent/TW200306823A/zh

2003-02-14 Priority to US10/366,703 priority patent/US20040006117A1/en

2003-09-04 Publication of DE10207843A1 publication Critical patent/DE10207843A1/de

2004-09-14 Priority to NO20043840A priority patent/NO20043840L/no

2004-09-14 Priority to ZA200407382A priority patent/ZA200407382B/en

2004-09-14 Priority to EC2004005297A priority patent/ECSP045297A/es

2006-02-09 Priority to US11/351,603 priority patent/US20060211690A1/en

Status Ceased legal-status Critical Current

Links

102000013462 Interleukin-12 Human genes 0.000 title claims abstract description 36
108010065805 Interleukin-12 Proteins 0.000 title claims abstract description 36
230000001404 mediated effect Effects 0.000 title claims abstract description 18
229940117681 interleukin-12 Drugs 0.000 title claims abstract description 12
239000003112 inhibitor Substances 0.000 title claims abstract description 10
108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 9
230000028993 immune response Effects 0.000 title abstract description 3
102100037850 Interferon gamma Human genes 0.000 title 1
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 20
238000011282 treatment Methods 0.000 claims abstract description 16
239000003814 drug Substances 0.000 claims abstract description 11
230000002025 microglial effect Effects 0.000 claims abstract description 10
238000002360 preparation method Methods 0.000 claims abstract description 10
208000026278 immune system disease Diseases 0.000 claims abstract description 9
102000008070 Interferon-gamma Human genes 0.000 claims abstract description 8
229960003130 interferon gamma Drugs 0.000 claims abstract description 8
230000028709 inflammatory response Effects 0.000 claims abstract description 3
-1 methanediylbisoxy Chemical group 0.000 claims description 97
150000003254 radicals Chemical class 0.000 claims description 68
229910052760 oxygen Inorganic materials 0.000 claims description 49
125000000217 alkyl group Chemical group 0.000 claims description 39
125000001072 heteroaryl group Chemical group 0.000 claims description 38
125000000753 cycloalkyl group Chemical group 0.000 claims description 30
229910052717 sulfur Inorganic materials 0.000 claims description 26
229910052794 bromium Inorganic materials 0.000 claims description 24
229910052801 chlorine Inorganic materials 0.000 claims description 24
229910052731 fluorine Inorganic materials 0.000 claims description 24
229910052757 nitrogen Inorganic materials 0.000 claims description 24
125000003118 aryl group Chemical group 0.000 claims description 23
125000004432 carbon atom Chemical group C* 0.000 claims description 21
125000005842 heteroatom Chemical group 0.000 claims description 21
229910052799 carbon Inorganic materials 0.000 claims description 17
125000004430 oxygen atom Chemical group O* 0.000 claims description 17
125000001589 carboacyl group Chemical group 0.000 claims description 16
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
125000001424 substituent group Chemical group 0.000 claims description 10
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
206010040070 Septic Shock Diseases 0.000 claims description 9
125000000623 heterocyclic group Chemical group 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
125000004434 sulfur atom Chemical group 0.000 claims description 9
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 8
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 7
208000023275 Autoimmune disease Diseases 0.000 claims description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
125000003342 alkenyl group Chemical group 0.000 claims description 6
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 5
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
206010003246 arthritis Diseases 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
208000002296 eclampsia Diseases 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
125000002950 monocyclic group Chemical group 0.000 claims description 4
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 4
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 4
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical group CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
206010012442 Dermatitis contact Diseases 0.000 claims description 3
208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
208000002029 allergic contact dermatitis Diseases 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 3
230000000172 allergic effect Effects 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
231100000673 dose–response relationship Toxicity 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
206010025135 lupus erythematosus Diseases 0.000 claims description 3
230000003959 neuroinflammation Effects 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
201000000306 sarcoidosis Diseases 0.000 claims description 3
230000036303 septic shock Effects 0.000 claims description 3
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 2
208000023328 Basedow disease Diseases 0.000 claims description 2
206010006895 Cachexia Diseases 0.000 claims description 2
208000027932 Collagen disease Diseases 0.000 claims description 2
208000015023 Graves' disease Diseases 0.000 claims description 2
208000001204 Hashimoto Disease Diseases 0.000 claims description 2
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
206010019663 Hepatic failure Diseases 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
241000721454 Pemphigus Species 0.000 claims description 2
206010035664 Pneumonia Diseases 0.000 claims description 2
206010035742 Pneumonitis Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
208000036142 Viral infection Diseases 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
125000002619 bicyclic group Chemical group 0.000 claims description 2
230000008105 immune reaction Effects 0.000 claims description 2
125000001041 indolyl group Chemical group 0.000 claims description 2
208000007903 liver failure Diseases 0.000 claims description 2
231100000835 liver failure Toxicity 0.000 claims description 2
KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
230000008816 organ damage Effects 0.000 claims description 2
125000005010 perfluoroalkyl group Chemical group 0.000 claims description 2
230000010410 reperfusion Effects 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
231100000331 toxic Toxicity 0.000 claims description 2
230000002588 toxic effect Effects 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 7
239000000126 substance Substances 0.000 description 32
210000004027 cell Anatomy 0.000 description 31
108060008682 Tumor Necrosis Factor Proteins 0.000 description 22
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 21
150000001875 compounds Chemical class 0.000 description 19
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 15
239000000243 solution Substances 0.000 description 15
239000002158 endotoxin Substances 0.000 description 13
238000005516 engineering process Methods 0.000 description 11
229920006008 lipopolysaccharide Polymers 0.000 description 11
206010061218 Inflammation Diseases 0.000 description 10
230000004054 inflammatory process Effects 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
239000003826 tablet Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
239000012980 RPMI-1640 medium Substances 0.000 description 7
210000002443 helper t lymphocyte Anatomy 0.000 description 7
238000000034 method Methods 0.000 description 7
210000001616 monocyte Anatomy 0.000 description 7
229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
125000000896 monocarboxylic acid group Chemical group 0.000 description 6
230000004913 activation Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000031261 interleukin-10 production Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
210000000274 microglia Anatomy 0.000 description 5
210000000822 natural killer cell Anatomy 0.000 description 5
239000000047 product Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
230000001960 triggered effect Effects 0.000 description 5
102000003814 Interleukin-10 Human genes 0.000 description 4
108090000174 Interleukin-10 Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108010047620 Phytohemagglutinins Proteins 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
150000001735 carboxylic acids Chemical class 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
238000000432 density-gradient centrifugation Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000008298 dragée Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000001885 phytohemagglutinin Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
UAGFINZVDPJCIQ-UHFFFAOYSA-N 6-[3-(4-methylphenyl)-2-phenylbenzimidazol-5-yl]oxyhexanoic acid Chemical compound C1=CC(C)=CC=C1N1C2=CC(OCCCCCC(O)=O)=CC=C2N=C1C1=CC=CC=C1 UAGFINZVDPJCIQ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
210000000447 Th1 cell Anatomy 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
210000001787 dendrite Anatomy 0.000 description 2
239000000975 dye Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000019734 interleukin-12 production Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
230000003950 pathogenic mechanism Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000001991 pathophysiological effect Effects 0.000 description 2
239000002304 perfume Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000000518 rheometry Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
GZPMMQGPHXEMSZ-UHFFFAOYSA-N 1-(methoxymethyl)pyrrolidine Chemical compound COCN1CCCC1 GZPMMQGPHXEMSZ-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical compound CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
208000037487 Endotoxemia Diseases 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
229940126530 T cell activator Drugs 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
238000006887 Ullmann reaction Methods 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000004450 alkenylene group Chemical group 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005529 alkyleneoxy group Chemical group 0.000 description 1
125000004419 alkynylene group Chemical group 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000002993 cycloalkylene group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
229940080345 gamma-cyclodextrin Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
102000052620 human IL10 Human genes 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229940088592 immunologic factor Drugs 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007302 negative regulation of cytokine production Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000006764 neuronal dysfunction Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229940075065 polyvinyl acetate Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

DE10207843A 2002-02-15 2002-02-15 Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen Ceased DE10207843A1 (de)

Priority Applications (23)

Application Number	Priority Date	Filing Date	Title
DE10207843A DE10207843A1 (de)	2002-02-15	2002-02-15	Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
YU71304A RS71304A (sr)	2002-02-15	2003-01-17	INHIBITORI MIKROGLIA ZA PREKIDANJE IMUNIH REAKCIJA POSREDOVANIH INTERLEUKINOM-12 I FNγ
JP2003567407A JP2005522447A (ja)	2002-02-15	2003-01-17	インターロイキン１２及びＩＦＮγにより介在される免疫反応を中断するための微小グリア細胞インヒビター
AU2003245523A AU2003245523A1 (en)	2002-02-15	2003-01-17	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
BR0307706-3A BR0307706A (pt)	2002-02-15	2003-01-17	Inibidores de microglia para a interrupção da interleucina 12 e reações imunológicas induzidas por ifn-gama
KR10-2004-7012557A KR20040084909A (ko)	2002-02-15	2003-01-17	인터루킨 12 및 ＩＦＮγ에 의하여 유도되는 면역 반응을차단하기 위한 소교세포 억제제
CNA038039923A CN1756546A (zh)	2002-02-15	2003-01-17	用于阻断白细胞介素12和IFNγ介导的免疫反应的小胶质细胞抑制剂
CA002475770A CA2475770A1 (en)	2002-02-15	2003-01-17	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn.gamma.g(g)
PCT/EP2003/000467 WO2003068225A1 (de)	2002-02-15	2003-01-17	Mikroglia-inhibitoren zur unterbrechung von interleukin 12 und ifn-gamma vermittelten immunreaktionen
MXPA04007943A MXPA04007943A (es)	2002-02-15	2003-01-17	Inhibidores de microglia para interrumpir reacciones inmunologicas inducidas por interleucina 12 e ifn-gamma.
UA20040907401A UA81111C2 (en)	2002-02-15	2003-01-17	Use of a microglia inhibitor for the production of a pharmaceutical agent that inhibits immune reactions mediated by interleukin 12 (il 12) and interferon-? (variants)
PL03371327A PL371327A1 (en)	2002-02-15	2003-01-17	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
RU2004127677/15A RU2004127677A (ru)	2002-02-15	2003-01-17	Ингибиторы микроглии для прерывания опосредуемых интерлейкином 12 и у-интерфероном иммунных реакций
EP03739380A EP1474138A1 (de)	2002-02-15	2003-01-17	Mikroglia-inhibitoren zur unterbrechung von interleukin 12 und ifn-gamma vermittelten immunreaktionen
PE2003000119A PE20030906A1 (es)	2002-02-15	2003-02-03	INHIBIDORES DE LA MICROGLIA PARA INTERRUMPIR REACCIONES INMUNES ASOCIADAS CON INTERLEUCINA 12 Y IFNy
UY27662A UY27662A1 (es)	2002-02-15	2003-02-11	Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny.
ARP030100436A AR039556A1 (es)	2002-02-15	2003-02-12	Inhibidores de la microglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn gamma
TW092103072A TW200306823A (en)	2002-02-15	2003-02-14	Microglia inhibitors for interrupting interleukin 12 and Ifn γ -mediated immune
US10/366,703 US20040006117A1 (en)	2002-02-15	2003-02-14	Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
NO20043840A NO20043840L (no)	2002-02-15	2004-09-14	Mikrogliahemmere til stopping av immunreaksjoner som er indusert av indusert av interleukin-12 og IFN-gamma
ZA200407382A ZA200407382B (en)	2002-02-15	2004-09-14	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and IFNy.
EC2004005297A ECSP045297A (es)	2002-02-15	2004-09-14	Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?
US11/351,603 US20060211690A1 (en)	2002-02-15	2006-02-09	Microglia inhibitors for interrupting interleukin 12 and IFNgamma-mediated immune reactions

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10207843A DE10207843A1 (de)	2002-02-15	2002-02-15	Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Publications (1)

Publication Number	Publication Date
DE10207843A1 true DE10207843A1 (de)	2003-09-04

Family

ID=27674912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE10207843A Ceased DE10207843A1 (de)	2002-02-15	2002-02-15	Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Country Status (21)

Country	Link
EP (1)	EP1474138A1 (es)
JP (1)	JP2005522447A (es)
KR (1)	KR20040084909A (es)
CN (1)	CN1756546A (es)
AR (1)	AR039556A1 (es)
AU (1)	AU2003245523A1 (es)
BR (1)	BR0307706A (es)
CA (1)	CA2475770A1 (es)
DE (1)	DE10207843A1 (es)
EC (1)	ECSP045297A (es)
MX (1)	MXPA04007943A (es)
NO (1)	NO20043840L (es)
PE (1)	PE20030906A1 (es)
PL (1)	PL371327A1 (es)
RS (1)	RS71304A (es)
RU (1)	RU2004127677A (es)
TW (1)	TW200306823A (es)
UA (1)	UA81111C2 (es)
UY (1)	UY27662A1 (es)
WO (1)	WO2003068225A1 (es)
ZA (1)	ZA200407382B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10207844A1 (de) *	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE602005016729D1 (de) *	2005-03-17	2009-10-29	Proyecto Biomedicina Cima Sl	Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
WO2013186229A1 (en) *	2012-06-11	2013-12-19	Ucb Pharma S.A.	Tnf -alpha modulating benzimidazoles
US9586949B2 (en)	2015-02-09	2017-03-07	Incyte Corporation	Aza-heteroaryl compounds as PI3K-gamma inhibitors
LT3371190T (lt)	2015-11-06	2022-08-10	Incyte Corporation	Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
DK3390367T3 (da) *	2015-12-15	2020-10-26	Univ Leland Stanford Junior	Fremgangsmåde til forebyggelse og/eller behandling af aldersrelateret kognitiv funktionsnedsættelse og neuroinflammation
AR107293A1 (es)	2016-01-05	2018-04-18	Incyte Corp	COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
US10138248B2 (en)	2016-06-24	2018-11-27	Incyte Corporation	Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
WO2019079469A1 (en)	2017-10-18	2019-04-25	Incyte Corporation	CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
CR20250050A (es)	2018-09-05	2025-03-19	Incyte Corp	Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
PL3860998T3 (pl)	2018-10-05	2024-06-17	Annapurna Bio Inc.	Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj
CN112341450B (zh) *	2019-08-09	2022-05-17	成都先导药物开发股份有限公司	一种免疫调节剂
CN112341451B (zh) *	2019-08-09	2022-06-17	成都先导药物开发股份有限公司	一种免疫调节剂
WO2021126923A1 (en) *	2019-12-19	2021-06-24	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Cd206 modulators their use and methods for preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003004023A1 (de) *	2001-07-06	2003-01-16	Schering Aktiengesellschaft	1-alkyl-2-aryl-benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln sowie diese derivate enthaltende pharmazeutische präparate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4330959A1 (de) *	1993-09-09	1995-03-16	Schering Ag	Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2396227C (en) *	2000-01-14	2012-03-20	Schering Aktiengesellschaft	1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
DE10135050A1 (de) *	2001-07-09	2003-02-06	Schering Ag	1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

2002
- 2002-02-15 DE DE10207843A patent/DE10207843A1/de not_active Ceased
2003
- 2003-01-17 KR KR10-2004-7012557A patent/KR20040084909A/ko not_active Ceased
- 2003-01-17 UA UA20040907401A patent/UA81111C2/uk unknown
- 2003-01-17 CN CNA038039923A patent/CN1756546A/zh active Pending
- 2003-01-17 RS YU71304A patent/RS71304A/sr unknown
- 2003-01-17 CA CA002475770A patent/CA2475770A1/en not_active Abandoned
- 2003-01-17 PL PL03371327A patent/PL371327A1/xx not_active Application Discontinuation
- 2003-01-17 WO PCT/EP2003/000467 patent/WO2003068225A1/de not_active Ceased
- 2003-01-17 RU RU2004127677/15A patent/RU2004127677A/ru unknown
- 2003-01-17 BR BR0307706-3A patent/BR0307706A/pt not_active IP Right Cessation
- 2003-01-17 EP EP03739380A patent/EP1474138A1/de not_active Withdrawn
- 2003-01-17 JP JP2003567407A patent/JP2005522447A/ja active Pending
- 2003-01-17 AU AU2003245523A patent/AU2003245523A1/en not_active Abandoned
- 2003-01-17 MX MXPA04007943A patent/MXPA04007943A/es unknown
- 2003-02-03 PE PE2003000119A patent/PE20030906A1/es not_active Application Discontinuation
- 2003-02-11 UY UY27662A patent/UY27662A1/es not_active Application Discontinuation
- 2003-02-12 AR ARP030100436A patent/AR039556A1/es unknown
- 2003-02-14 TW TW092103072A patent/TW200306823A/zh unknown
2004
- 2004-09-14 EC EC2004005297A patent/ECSP045297A/es unknown
- 2004-09-14 ZA ZA200407382A patent/ZA200407382B/en unknown
- 2004-09-14 NO NO20043840A patent/NO20043840L/no not_active Application Discontinuation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003004023A1 (de) *	2001-07-06	2003-01-16	Schering Aktiengesellschaft	1-alkyl-2-aryl-benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln sowie diese derivate enthaltende pharmazeutische präparate
DE10134775A1 (de) *	2001-07-06	2003-01-30	Schering Ag	1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yukihiko A. u.a.: A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. In: Journal of Neuroimmunology 89 (1998) S.35-42 *

Also Published As

Publication number	Publication date
CA2475770A1 (en)	2003-08-21
PL371327A1 (en)	2005-06-13
UY27662A1 (es)	2003-09-30
WO2003068225A1 (de)	2003-08-21
ECSP045297A (es)	2004-10-26
KR20040084909A (ko)	2004-10-06
BR0307706A (pt)	2005-01-11
AU2003245523A1 (en)	2003-09-04
ZA200407382B (en)	2005-09-14
CN1756546A (zh)	2006-04-05
AR039556A1 (es)	2005-02-23
RU2004127677A (ru)	2005-06-10
UA81111C2 (en)	2007-12-10
EP1474138A1 (de)	2004-11-10
JP2005522447A (ja)	2005-07-28
PE20030906A1 (es)	2004-01-17
TW200306823A (en)	2003-12-01
RS71304A (sr)	2006-10-27
MXPA04007943A (es)	2004-11-26
NO20043840L (no)	2004-11-12

Publication	Publication Date	Title
DE10207843A1 (de)	2003-09-04	Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
DE69924607T2 (de)	2006-02-02	Benzimidazol-derivate als ige-modulatoren
DE69929996T2 (de)	2006-11-16	Pharmazeutisches mittel zur behandlung von diabetes
EP1294682B1 (de)	2004-04-28	Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60130799T2 (de)	2008-07-17	Synthese von 4-aminothalidomid enantiomeren
DE60125980T2 (de)	2007-10-25	P38kinase-inhibitoren vom piperidin/piperazin-typ
DE69932154T2 (de)	2007-05-31	Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
DE69425334T2 (de)	2001-02-08	6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
EP1113809B1 (de)	2005-04-06	Pharmazeutische zubereitung enthaltend ein cyclo-peptide und ein chemotherapeutikum oder einen angiogeneseinhibitor
WO1991017748A1 (de)	1991-11-28	Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
EP1218341A1 (de)	2002-07-03	Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69732428T2 (de)	2005-12-29	Thiazolderivate für die inhibierung der zytokinproduktion beziehungsweise der zelladhäsion
EP0688771B1 (de)	2001-07-11	Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
WO2000020410A1 (de)	2000-04-13	Mit heterocyclen substituierte propanolaminderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP1465613A2 (de)	2004-10-13	KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
US20040006117A1 (en)	2004-01-08	Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
DE60020556T2 (de)	2005-10-27	Ionenkanal modulierende mittel
DE3873210T2 (de)	1993-02-18	Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
EP1474415B1 (de)	2011-07-27	1-phenyl-2-heteroaryl-substituierte benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln zur behandlung von immunologischen erkrankungen
DE60221104T2 (de)	2008-03-13	Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
DE60218203T2 (de)	2008-01-03	Verbindungen und verfahren zur behandlung einer hyperaktiven blase
EP0270482B1 (de)	1993-10-27	Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen
JPH0377824A (ja)	1991-04-03	トリフルオロメチルフェニルテトラヒドロピリジン誘導体を含む腸管運動障害の予防用および／または治療用医薬製剤
US3923993A (en)	1975-12-02	Process for treating neuroendocrinopathic diseases employing fluspirilene
WO1994007497A1 (de)	1994-04-14	VERWENDUNG VON DOPAMINAGONISTEN ZUR AKTIVIERUNG DER η-INTERFERON-PRODUKTION

Legal Events

Date	Code	Title	Description
2003-09-04	OP8	Request for examination as to paragraph 44 patent law
2007-05-31	8127	New person/name/address of the applicant	Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE
2008-03-27	8127	New person/name/address of the applicant	Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE
2009-02-05	8131	Rejection